Studies confirm that drug-coated balloons can replace stents – even in larger coronary arteries

Numerous clinical studies have already shown that drug-coated balloons are at least as effective, and in some cases superior, to drug-eluting stents in treating atherosclerosis in smaller vessels (up to 2.75 mm in diameter). The method has been used millions of times in clinical practice. In Asia in particular, DCB therapy has already replaced nearly half of all interventions where drug-eluting stents would previously have been used. Studies demonstrating the efficacy of DCBs in treating small coronary vessels have been published by Scheller and colleagues in leading journals such as The Lancet (Lancet. 2018 Sep 8; 392(10150): 849-856; Lancet. 2020 Nov 7; 396(10261): 1504-1510) and the European Heart Journal (Eur Heart J. 2025 May 2; 46(17): 1586-1599). An international expert group, the Academic Research Consortium (ARC), recently published treatment guidelines for DCBs in both the European Heart Journal (Eur Heart J. 2025 Jul 7; 46(26): 2498-2519) and the Journal of the American College of Cardiology, (J Am Coll Cardiol. 2025 Oct 14; 86(15): 1170-1202), with significant contributions in each case from Professor Scheller.

Now, a new international study (SELUTION DeNovo; Spaulding C. et al.) involving more than 3,300 patients has demonstrated that DCBs also offer a safe and effective means of treating coronary arteries with diameters larger than 2.75 mm, for which up until now stents have been the conventional treatment of choice. Stents are metal mesh tubes that are inserted into a narrowed or blocked blood vessel to act as a scaffold to keep it open. Until now, DCBs were primarily used in larger arteries by inserting the balloon into existing stents when these became blocked by new deposits.

But the SELUTION DeNovo study shows that DCBs also perform well in larger vessels. After one year, the rate of serious events such as sudden cardiac death, heart attack or the need for a repeat intervention was comparable to that observed with modern drug-eluting stents. ‘We know that drug-eluting stents are very safe. However, we also know that because the stent remains in the vessel, there is a risk of complications over the medium to long term,’ says Professor Scheller, who is Professor of Clinical and Experimental Interventional Cardiology at Saarland University and head of the Cardiac Catheterization Lab at Saarland University Medical Center in Homburg. ‘The advantage of drug-coated balloons is that they deliver medication locally without leaving a permanent implant behind in the vessel.’

The new study also qualifies the findings of the 2024 Chinese ‘Rec-Cagefree I’ study, which had suggested that stents were more effective than drug-coated balloons in treating larger vessels with uncomplicated stenoses (non-complex narrowing) over a two-year period, concluding that drug-coated balloons did not provide lasting efficacy in such cases. At the TCT conference in San Francisco, both the SELUTION DeNovo results and updated three-year data from Rec-Cagefree I study were presented. Professor Scheller discussed these findings with other leading global experts during one of the TCT main sessions.

‘The results of the Rec-Cagefree I study cannot be applied to our method,' says Scheller. After the original patent for DCBs expired, the Chinese researchers tested a coating that they developed themselves based on the original Charité patent by Professors Scheller and Speck. ‘Their coating differs significantly from ours, not least in terms of drug composition and particle size. The active ingredients used in the Chinese study do not remain in the vessel wall long enough, which makes long-term prevention of restenosis difficult to achieve,’ explains Scheller. He and other authors have outlined their critique in a letter to the editor published in The Lancet (Lancet. 2025 Oct 25; 406(10514): 1950-1951)*.

‘In addition to comparing different technologies for treating coronary artery disease, my team and I are focused on developing new strategies tailored to individual patient needs,’ says Bruno Scheller. ‘For many patients, a combination of drug-eluting stents and drug-coated balloons DCBs will remain the best option. DCBs allows us to avoid long stent lengths, which can pose significant risks to patients over the medium to long term.'

‘The new data presented at the TCT conference supports our long-standing approach to interventional vascular therapy. We want to treat patients using as few permanent implants as possible,’ says Scheller. His research group in Homburg is a global leader in conducting experimental and clinical research in this field. Professor Scheller is also the global lead for some of the international clinical trials on DCBs that are currently underway in Homburg, with partners from Europe, Asia and the USA.

The SELUTION DeNovo study

Spaulding C., on behalf of the SELUTION DeNovo investigators One-year results of the SELUTION DeNovo trial comparing a strategy of PCI with a sirolimus-eluting balloon and provisional stenting versus systematic DES implantation to treat de novo coronary lesions. Presented at: TCT 2025. 26 October 2025. San Francisco, CA, USA.

Bruno Scheller and others have published their assessment of the 2024 study ‘Rec-Cagefree I’ in a recent letter to the editor of The Lancet. (Lancet. 2025 Oct 25; 406(10514): 1950-1951)

Reference: Studies confirm that drug-coated balloons can replace stents – even in larger coronary arteries, Saarland University, Meeting:TCT 2025: Transcatheter Cardiovascular Therapeutics